PARP Inhibitors Improve Outcomes, QOL in Breast Cancer

Article

Not only are PARP inhibitors proving to be an efficacious treatment for patients with metastatic breast cancer, but they're also improving quality of life, too.

When given an oral agent such as a PARP inhibitor, patients with metastatic breast cancer reported that they felt more in control of their life, something that Jennifer Litton, MD, of the The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology, called a “game changer.”

While these agents improve quality of life, they are also proving to be clinically efficacious, too. Both the EMBRACA trial (studying talazoparib in patients with metastatic breast cancer with a BRCA mutation) and the OLYMPIAD trial (studying olaparib for patients with metastatic breast cancer with a BRCA mutation) are showing that PARP inhibition therapy can improve treatment outcomes compared to standard-of-care chemotherapy in this patient population.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Photo of a woman with brown hair and bangs, surrounded by a blue border
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.